Payment overview · 2025
General Payments
$259.01
13 reported records · 8 companies
Healthcare provider profile · identity verified
Paul B Cardali, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MORRISTOWN, TN · NPI 1235180159
Verified facts
What the public records show
CMS Open Payments records show Paul B Cardali, MD received $259.01 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.49 | 27.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.60 | 20.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.11 | 13.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.69 | 10.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.39 | 7.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.37 | 7.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.07 | 6.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.29 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $259.01 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.49 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.60 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 630 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 471 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 76 |
| Lisinopril | Lisinopril | 217 | 60 |
| Jardiance | Empagliflozin | 209 | 53 |
| Montelukast Sodium | Montelukast Sodium | 208 | 59 |
| Omeprazole | Omeprazole | 197 | 50 |
| Gabapentin | Gabapentin | 169 | 34 |
| Furosemide | Furosemide | 155 | 48 |
| Metformin Hcl Er | Metformin Hcl | 154 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 143 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 38 |
| Losartan Potassium | Losartan Potassium | 138 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 64 |
| Ozempic | Semaglutide | 127 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 32 |
| Meloxicam | Meloxicam | 120 | 37 |
| Bumetanide | Bumetanide | 115 | 40 |
| Pregabalin | Pregabalin | 109 | 17 |
| Metformin Hcl | Metformin Hcl | 106 | 33 |
| Potassium Chloride | Potassium Chloride | 105 | 34 |
| Allopurinol | Allopurinol | 101 | 29 |
| Trazodone Hcl | Trazodone Hcl | 100 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 26 |
| Farxiga | Dapagliflozin Propanediol | 96 | 21 |
| Celecoxib | Celecoxib | 91 | 29 |
| Eliquis | Apixaban | 81 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 25 |
| Carvedilol | Carvedilol | 76 | 22 |
| Myrbetriq | Mirabegron | 76 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 14 |
| Entresto | Sacubitril/Valsartan | 71 | 18 |
| Trulicity | Dulaglutide | 71 | 18 |
| Cefdinir | Cefdinir | 70 | 55 |
| Ramipril | Ramipril | 69 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 37 |
| Candesartan Cilexetil | Candesartan Cilexetil | 67 | 19 |
| Spironolactone | Spironolactone | 67 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 12 |
| Donepezil Hcl | Donepezil Hcl | 66 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 19 |
| Tramadol Hcl | Tramadol Hcl | 63 | 18 |
| Risedronate Sodium | Risedronate Sodium | 62 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 25 |
| Xarelto | Rivaroxaban | 61 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 55 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Famotidine | Famotidine | 58 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 28 |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Mounjaro | Tirzepatide | 53 | 14 |
| Prednisone | Prednisone | 53 | 26 |
| Linzess | Linaclotide | 50 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | 14 |
| Simvastatin | Simvastatin | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 11 |
| Ondansetron Odt | Ondansetron | 45 | 26 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | 11 |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 15 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 39 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 35 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 12 |
| Methylprednisolone | Methylprednisolone | 31 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Tradjenta | Linagliptin | 29 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | 11 |
| Baclofen | Baclofen | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 13 |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | 18 |
| Acyclovir | Acyclovir | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Rybelsus | Semaglutide | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Droxidopa | Droxidopa | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $259.01 · 13 records | Novo Nordisk Inc | Cologuard Collection Kit, EVENITY, FARXIGA, JARDIANCE, MINIMED 780G, NUCALA, Ozempic, PROLIA, Rybelsus | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error